Hostname: page-component-77c78cf97d-4gwwn Total loading time: 0 Render date: 2026-04-24T19:18:24.187Z Has data issue: false hasContentIssue false

Minor salivary gland carcinomas of oral cavity and oropharynx

Published online by Cambridge University Press:  22 May 2009

H Chijiwa*
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
K Sakamoto
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
H Umeno
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
T Nakashima
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan
G Suzuki
Affiliation:
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
N Hayafuchi
Affiliation:
Department of Radiology, Kurume University School of Medicine, Kurume, Japan
*
Address for correspondence: Dr Hideki Chijiwa, Department of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan. Fax: +81 942 37 1200 E-mail: chijiwah@med.kurume-u.ac.jp
Rights & Permissions [Opens in a new window]

Abstract

This paper reviews 22 cases of minor salivary gland carcinoma of the oral cavity or oropharynx which were treated at Kurume University Hospital between 1976 and 2005. Minor salivary gland carcinoma was observed in eight of 362 patients with cancer of the oral cavity (2 per cent), and in 14 of 275 patients with cancer of the oropharynx (5 per cent). The five-year and 10-year survival rates of patients with oropharyngeal minor salivary gland carcinoma were 90 per cent. No statistically significant difference was observed between survival rates for oropharyngeal minor salivary gland carcinoma and for oropharyngeal squamous cell carcinoma (p = 0.06). The five- and 10-year survival rates of patients with oral cavity minor salivary gland carcinoma were 75 and 37 per cent, respectively. No statistically significant difference was observed between survival rates for oral cavity minor salivary gland carcinoma and oral cavity squamous cell carcinoma.

Patients' survival results correlated well with the clinical stage of their lesions. A significant difference in survival was observed, comparing stage IV with stages I, II and III (p = 0.04). In contrast, no significant relationship was found between either survival and tumour type or survival and treatment. Adjuvant therapy is recommended for patients with grade III adenoid cystic carcinoma with perineural infiltration or intravascular infiltration.

Information

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2009
Figure 0

Table I Patients' tumour–node classification

Figure 1

Table II Minor salivary gland carcinomas: primary sites, tumour types and prevalence

Figure 2

Fig. 1 Survival rates for patients with oropharyngeal minor salivary gland carcinoma (grey line; n = 12) and oropharyngeal squamous cell carcinoma (black line; n = 261). p = 0.06, comparing the two survival rates.

Figure 3

Fig. 2 Survival rates for patients with oral cavity minor salivary gland carcinoma (grey line; n = 8) and oral cavity squamous cell carcinoma (black line; n = 354). The difference between the two rates was not significant.

Figure 4

Fig. 3 Patients' survival rates according to disease stage: stage I (black line), stage II (light grey line); stage III (dark grey line) or stage IV (stippled line). p = 0.04, comparing stage IV patient survival with the survival of patients with stages I, II or III.

Figure 5

Fig. 4 Patients' survival rates according to tumour type: basal cell carcinoma (grey line; n = 1); adenoid cystic carcinoma (black line; n = 13); mucoepidermoid carcinoma (hatched line; n = 5); and adenocarcinoma (dashed line; n = 1). The differences between these survival rates were not significant.

Figure 6

Fig. 5 Patients' survival rates according to treatment method: surgery + radiotherapy (stippled line; n = 12); surgery (black line; n = 6); or surgery + chemotherapy (grey line; n = 2). The differences between these survival rates were not significant.

Figure 7

Table III Cause of death, by tumour type and stage

Figure 8

Table IV Patients with mucoepidermoid carcinoma: clinical course and histopathological findings

Figure 9

Table V Patients with adenoid cystic carcinoma: clinical course and histopathological findings